<DOC>
	<DOCNO>NCT00209092</DOCNO>
	<brief_summary>The purpose study find combination docetaxel capecitabine shrink size breast tumor preserve breast .</brief_summary>
	<brief_title>Randomized Phase II Trial Induction Therapy Early Stage Breast Cancer</brief_title>
	<detailed_description>The purpose study identify new chemotherapy treatment regimens good response rate find combination docetaxel capecitabine shrink size breast tumor preserve breast . Induction chemotherapy offer possibility le surgery determines tumor sensitivity vivo . Previous trial demonstrate complete pathologic response breast surgery correspond improved outcome . Additionally , correlate specific molecular marker breast tumor chemotherapy , response treatment . Expression molecular market may use future predict likelihood response chemotherapy give post-operatively .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm breast carcinoma . Early stage breast cancer ( stage 1 , 2 , 3 ) . No evidence disease outside breast chest wall , except ipsilateral axillary lymph node . 18 year age old . Final eligibility clinical trial determine health professional conduct trial . Prior chemotherapy , hormonal therapy , biologic therapy radiation therapy breast cancer . Major surgery within 28 day study entry . Evidence central nervous system ( CNS ) metastases . Final eligibility clinical trial determine health professional conduct trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>